Despite disappointing results in the genetic neurodegenerative disorder, the drug shows potential for treating obesity.
California-based BridgeBio has secured US FDA approval for its lead candidate drug, acoramidis (brand name Attruby) for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback